Management Or Ownership Change
Expected: Feb 2026LOW confidence
What: Board Appointment: Dr. Swati Patankar
Unichem Laboratories Ltd: Stock Analysis & Fundamentals
Updated this weekUnichem Laboratories Ltd (Pharma - Others) — fundamental analysis, earnings data, and key metrics. PE: 25.8. ROE: 5.6%. This stock is not currently in the Nifty 500 momentum outperformers list.
Unichem Laboratories Ltd Key Facts
Earnings Acceleration Triggers
1. Management Or Ownership Change
Feb 2026LOW
Key Risks
1. Settlement of €19
HIGH2. USFDA inspection of Kolhapur API facility in Feb 2026 resulted in five procedura
MEDIUMSector-Specific Signals
FDA Inspection Status5 Observations
Standalone Revenue Growth₹314.90 Cr-29.69%
Operating Margin (Excl. Other Income)8.59%-746 bps
Key Numbers
Current Price
₹386
Market Cap
2.7K Cr
Valuation
N/AWhy Are Unichem Laboratories Ltd's Earnings Accelerating?
Based on Q3 FY26 (web) earnings • Updated Apr 18, 2026
What Are the Key Risks for Unichem Laboratories Ltd?
Earnings deceleration risks from management commentary
Settlement of €19
HIGHTrigger: Settlement of €19.49 million (₹175 Cr) fine with European Commission regarding Perindopril patent dispute.
Impact: PAT impact: ₹175 Cr
Management view: Paid €16.75 million in Oct 2025 to conclude the matter.
Monitor: litigation
USFDA inspection of Kolhapur API facility in Feb 2026 resulted in five procedura
MEDIUMTrigger: USFDA inspection of Kolhapur API facility in Feb 2026 resulted in five procedural observations.
Management view: Stated observations are procedural and not data integrity related; response within 15 days.
Monitor: regulatory
What Did Unichem Laboratories Ltd Report This Quarter?
Headline numbers from the latest earnings call
Revenue
₹521.17 Cr
YoY -2.24%QoQ -9.98%
Revenue hit the lowest quarterly level in FY26, underperforming the broader stable pharmaceutical sector.
EBITDA
₹44.78 Cr
YoY -47.65%Margin 8.59%
Core operating profitability nearly halved YoY as margins compressed by 746 basis points.
PAT
₹264.29 Cr
YoY +356.85%QoQ +2322.79%
Headline PAT was heavily inflated by a one-time exceptional gain of ₹275.52 Cr from land and building sales.
Other Highlights
• Exceptional gain of ₹275.52 Cr from sale of land and buildings drove PAT surge.
• Standalone revenue plummeted 29.69% YoY to ₹314.90 Cr.
• Operating margin (excl. OI) compressed 746 bps YoY to 8.59%.
What Sector Metrics Matter for Unichem Laboratories Ltd?
Sub-sector-specific signals from the latest concall — each with management's stated reason for the change
FDA Inspection Status
5 Observations
Why: USFDA inspection at Kolhapur API site in Feb 2026 concluded with procedural observations.
Standalone Revenue Growth
₹314.90 Cr
YoY -29.69%
Why: Sharp decline suggests operational challenges or slowdown in key business segments.
Operating Margin (Excl. Other Income)
8.59%
YoY -746 bpsQoQ -284 bps
Why: Persistent pressure on core business operations and lack of pricing power.
What Is Unichem Laboratories Ltd's Management Guidance?
Forward-looking targets from management
Management Tone: CAUTIOUS
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Apr 18, 2026.
Other Top Pharma - Others Stocks Beating Nifty 500
Frequently Asked Questions: Unichem Laboratories Ltd
Based on publicly available financial data. This is educational research, not investment advice.
What were Unichem Laboratories Ltd's latest quarterly results?
Unichem Laboratories Ltd's latest quarterly results (Dec 2025) show
- PAT Growth YoY: +355.2%
- Revenue Growth YoY: -2.3%
- Operating Margin: 9.0%
What is Unichem Laboratories Ltd's current PE ratio?
Unichem Laboratories Ltd's current PE ratio is 25.8x.
- Current PE: 25.8x
- Market Cap: 2.7K Cr
What is Unichem Laboratories Ltd's price-to-book ratio?
Unichem Laboratories Ltd's price-to-book ratio is 1.1x.
- Price-to-Book (P/B): 1.1x
- Book Value per Share: ₹346
- Current Price: ₹386
Is Unichem Laboratories Ltd a fundamentally strong company?
Unichem Laboratories Ltd's fundamental strength based on key financial ratios
- Return on Capital (ROCE): 6.0%
Is Unichem Laboratories Ltd debt free?
Unichem Laboratories Ltd has a debt-to-equity ratio of N/A.
- Total Debt: ₹502 Cr
What is Unichem Laboratories Ltd's return on equity (ROE) and ROCE?
Unichem Laboratories Ltd's return ratios over recent years
- FY2023: ROCE -5.0%
- FY2024: ROCE 0.0%
- FY2025: ROCE 6.0%
Is Unichem Laboratories Ltd's cash flow positive?
Unichem Laboratories Ltd's operating cash flow is negative (FY2025).
- Cash from Operations (CFO): ₹-7 Cr
- Free Cash Flow (FCF): ₹-249 Cr
- CFO/PAT Ratio: -5% (weak cash conversion)
What is Unichem Laboratories Ltd's dividend yield?
Unichem Laboratories Ltd currently does not pay a significant dividend (yield 0.00%).
- Dividend Yield: 0.00%
- Current Price: ₹386
Who holds Unichem Laboratories Ltd shares — promoters, FII, DII?
Unichem Laboratories Ltd's shareholding pattern (Mar 2026)
- Promoters: 70.2%
- FII (Foreign): 1.0%
- DII (Domestic): 10.6%
- Public: 18.1%
Is promoter holding increasing or decreasing in Unichem Laboratories Ltd?
Unichem Laboratories Ltd's promoter holding has remained stable recently.
- Current Promoter Holding: 70.2% (Mar 2026)
- Previous Quarter: 70.2% (Dec 2025)
- Change: 0.00% (stable)
Is Unichem Laboratories Ltd a new momentum entry or an established outperformer?
Unichem Laboratories Ltd is an established outperformer with 1 weeks of consecutive Nifty 500 outperformance.
What are the growth catalysts for Unichem Laboratories Ltd?
Unichem Laboratories Ltd has 1 key growth catalyst identified from recent earnings analysis
- Management Or Ownership Change — Board changes are procedural and unlikely to drive immediate PAT inflection.
What are the key risks in Unichem Laboratories Ltd?
Unichem Laboratories Ltd has 2 key risks worth monitoring
- [HIGH] Settlement of €19 — Settlement of €19.49 million (₹175 Cr) fine with European Commission regarding Perindopril patent dispute.
- [MEDIUM] USFDA inspection of Kolhapur API facility in Feb 2026 resulted in five procedura — USFDA inspection of Kolhapur API facility in Feb 2026 resulted in five procedural observations.
What is Unichem Laboratories Ltd's management guidance for growth?
Unichem Laboratories Ltd's management has provided the following forward guidance
- Revenue outlook: Not Given
- Margin outlook: Not Given
- Management tone: cautious
What sector-specific metrics matter most for Unichem Laboratories Ltd?
Unichem Laboratories Ltd's most important sub-sector-specific KPIs from the latest concall
- FDA Inspection Status: 5 Observations — USFDA inspection at Kolhapur API site in Feb 2026 concluded with procedural observations.
- Standalone Revenue Growth: ₹314.90 Cr (YoY -29.69%) — Sharp decline suggests operational challenges or slowdown in key business segments.
- Operating Margin (Excl. Other Income): 8.59% (YoY -746 bps) (QoQ -284 bps) — Persistent pressure on core business operations and lack of pricing power.
Is Unichem Laboratories Ltd worth studying for long term investment?
Based on quantitative research signals, here is why Unichem Laboratories Ltd may be worth studying
- Currently showing mixed signals — monitor for clearer trend confirmation
What is the investment thesis for Unichem Laboratories Ltd?
Unichem Laboratories Ltd investment thesis summary:
Research Signals (Bull Case)
- Growth catalyst: Management Or Ownership Change
Risk Factors (Bear Case)
- Key risk: Settlement of €19
What is the future outlook for Unichem Laboratories Ltd?
Unichem Laboratories Ltd's forward outlook based on current data signals
- Key Catalyst: Management Or Ownership Change
- Key Risk: Settlement of €19
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.